Background
==========

Sublingual allergen immunotherapy is an effective treatment for allergic respiratory diseases.[@b1-jaa-9-129],[@b2-jaa-9-129] It has proven to be effective even after completion of the treatment[@b3-jaa-9-129] and prevents the development of asthma in subjects with allergic rhinitis.[@b4-jaa-9-129] Most studies show that it is a safe treatment, even if the administration is initiated by the maintenance dose.[@b5-jaa-9-129] SLITone^ULTRA®^ (ALK-Abelló, SA, Madrid, Spain) is a product containing high concentrations of allergens; its safety and treatment regimen have been previously established.[@b6-jaa-9-129] The factors associated with the occurrence of adverse reactions, besides the dosage,[@b7-jaa-9-129] have not been studied. The aim of this study was to determine the factors linked to this product in a routine clinical setting.

Methods
=======

Study design
------------

This was a noninterventional, observational, multicenter, open-label study carried out with the collaboration of 18 Spanish centers. The study was approved by the Comité Etico de Investigación Clínica del Complejo Hospitalario de Toledo, Toledo, Spain. All study participants (or their legal guardians when younger than 18 years) provided a written informed consent statement.

The study is registered in the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) database under the code ENCePP/SDPP/6012.

Study population
----------------

The inclusion criteria were diagnosis of allergic rhinoconjunctivitis with/without mild to moderate allergic asthma sensitized to grass, *Olea*, or house dust mites (*Dermatophagoides pteronyssinus/Dermatophagoides farinae*); positive skin prick test (wheal diameter ≥3 mm); and/or positivity to a specific IgE (IgE ≥class 2) according to the clinical routine of each investigator. Patients had to be treated with SLITone^ULTRA®^ for at least 3 months before being included in the study.

The exclusion criteria were patients participating in any clinical trial or research.

Treatment
---------

SLITone^ULTRA®^ is a biologically standardized allergenic extract presented in a single-dose container of 50 standardized reactivity units (SRU), 150 SRU, and 300 SRU.

The treatment schedule for the allergens included in this study is as follows: Initiation: 50 SRU/day for five consecutive days followed by 150 SRU/day for five additional consecutive days.Maintenance: 300 SRU/day (once a day). The treatment should be followed for at least 3 months.

The active ingredients included in this study were pollens (100% grass, 100% olive, or grass + *Olea europaea*) or mites (*D. pteronyssinus* or *D. pteronyssinus + D. farinae*).

Assessments
-----------

The possible factors associated with the occurrence of adverse reactions were classified into three groups as follows: patient related: age and sex;disease related (allergy): clinical diagnosis, presence of asthma, polysensitization, and years since the patient was first diagnosed; andtreatment related: immunotherapy composition and treatment phase.

Assessment of tolerability was performed by analyzing the adverse reactions (local or systemic) included in the medical history of patients. These reactions were coded as per the Medical Dictionary for Regulatory Activities Version 14.0; they were classified as either immediate (0--30 minutes after the administration of the immunotherapy) or delayed (\>30 minutes post administration), local or systemic, and mild (temporary symptoms with no effect on patient's everyday activities), moderate (notable symptoms, moderately affecting patient's everyday activities), or severe (symptoms affecting the patient's everyday activities considerably: unacceptable).

A secondary aim of this study was to assess the degree of compliance and the degree of satisfaction with the product. For this, the Morisky--Green test and the Treatment Satisfaction with Medicine Questionnaire were applied, respectively.

Calculation of sample size and statistical analysis
---------------------------------------------------

Based on previous studies with SLITone^ULTRA®^,[@b8-jaa-9-129] from which it was determined that 53% of the study subjects experienced adverse events (AEs), it was estimated that the percentage of subjects without exposure to a particular factor was somewhat lower (\~50%). Thus, a study designed with 200 subjects, with 5% level of significance and 80% of power, would allow us to determine the factors causing an increase of \>10% in the AEs.

The main objective of the study was to detect the risk factors associated (or not) with AEs. For this, the following equation was used:

Incidence of AEs: proportion of patients who had undergone any AE during the treatment. $$\frac{\text{Number~of~patients~with~any~adverse~event}}{\text{Total~number~of~patients}}$$

A univariate model was constructed for each possible risk factor. Significant factors were included (10% of significance) and were used along with their possible interactions to develop a multivariate logistic regression model.

Results
=======

A total of 183 study subjects were included in the study, of whom 8 were not considered in the analyses because they did not meet the inclusion criteria: 6 due to treatment duration (\<3 months once included in the study) and 2 for being younger than 5 years.

Of the 175 study subjects included in the analysis, 54.3% were women with a mean age of 21.2±15.5 years. All had allergic rhinitis and 93 (53.1%) also suffered from allergic asthma; 50.6% were polysensitized. The treatment composition for the study subjects (n/%) was as follows: 100% grass 30 subjects (18.0%), 100% *Olea* 32 subjects (19.2%), grass + *Olea* 39 subjects (23.4%), *Dermatophagoides* mix 32 subjects (19.2%), and *D. pteronyssinus* 34 subjects (20.4%). The mean treatment duration was 6.8 months, with a minimum of 3 months and a maximum of 52 months. One hundred and eighteen patients (68.6%) received concomitant medication: oral antihistamines 94 patients (54.7%), topical antihistamines 13 patients (7.6%), nasal corticosteroids 41 patients (23.8%), inhaled corticosteroids 34 patients (19.8%), oral corticosteroids two patients (1.2%), β-2 agonists 32 patients (18.6%), and antileukotrienes 14 patients (8.1%).

The adverse reactions registered in the study, coded as per the Medical Dictionary for Regulatory Activities, are shown in [Figure 1](#f1-jaa-9-129){ref-type="fig"}. The most frequent reaction was oral pruritus (13.7% of study patients). Other AEs occurred in \<5% of the subjects. Considering all AEs, most were local (84.7%) and immediate (93.5%). A total of 60.6% of the events occurred at the initiation phase of the treatment, more frequently when the highest dose was administered (67.7%). All reactions were mild to moderate. No serious adverse reactions were registered. In all, 80.6% of the events did not require any modification of the treatment plan. Regarding the allergen, *D. pteronyssinus*, the *Dermatophagoides* mix, *Olea*, and grass and grass + *Olea* were linked to AEs in 2.9%, 5.7%, 4%, and 5.1% of the patients, respectively. Tolerance was considered as good or very good in 94.8% of the subjects.

The causative factors possibly associated with the AEs are summarized in [Table 1](#t1-jaa-9-129){ref-type="table"}. Using the logistic regression multivariate model considering the two factors with the greatest influence on the occurrence of AEs (presence of asthma and duration of the treatment), a statistically significant interaction was observed between the two factors (*P*=0.0353). Thus, the influence of asthma varies depending on the duration of the treatment: in patients who were treated for 3 months, the influence is statistically significant (OR 3.21, 95% CI 1.27--8.08) and in patients who had been treated for \>3 months, it is not significant (OR 0.56, 95% CI 0.14--2.20).

Discussion
==========

There are limitations to this study. The first limitation is the small number of patients, which allowed us to detect only the factors that increase the number of AEs to 10%. Previous studies performed with the same product[@b6-jaa-9-129],[@b8-jaa-9-129] indicated that a value \<10% would not be clinically relevant.

The second limitation is the noninclusion of patients with allergic sensitization to other allergens different from those analyzed here, which could modify the tolerability pattern. However, the allergens included in this study are the most frequently prescribed allergens in Spain, and using other less prevalent allergens may have reduced the capacity of statistical analysis.

A third limitation is the design of the study; observational studies are considered to be at greater risk of bias. On the other hand, observational studies allow including children and adults, and we considered that age was an important factor to consider.

The aim of our study was to determine the risk factors associated with SLITone^ULTRA®^ tolerance in patients treated during the clinical practice. We found that treatment duration and asthma were the factors with the highest influence. In a previous study with other product administered sublingually, eg, GRAZAX^®^, it has been found that the occurrence of AEs is more frequently early in the treatment and tends to decrease.[@b9-jaa-9-129] On the other hand, a previous study performed with sublingual immunotherapy tablets showed that in patients with asthma and rhinoconjunctivitis, this treatment is safe and well tolerated.[@b10-jaa-9-129] Another possible factor may be the type of allergen administered. For this study, we used the most common allergens in our country, and no differences in tolerance between them were observed. Similarly, no effect was seen with other factors with potential influence, such as the age of the study subject, clinical diagnosis, or polysensitization.

The tolerability observed in our study is similar to that communicated in previous trials. Oral pruritus was the only adverse reaction registered in \>10% of the study patients, and all AEs were mild to moderate in severity. For many years, the good safety profile of sublingual immunotherapy was attributed to the use of extracts with low allergen concentration. However, recent investigations have established that the oral mucosa contains few or no mast cells, eosinophils, or basophils, and the integrity of the lamina propria is crucial for a limited contact between the allergen and the previously mentioned cells. This explains the good safety profile of products with a high allergen concentration.[@b11-jaa-9-129] On the other hand, the oral mucosa is rich in Langerhans-like dendritic cells expressing high affinity to the IgE receptor and toll-like receptors. Following activation of these receptors, the cells produce IL-10 and TGF-β, indicating that these cells are crucial in maintaining allergen tolerance.[@b11-jaa-9-129],[@b12-jaa-9-129]

Conclusion
==========

Our results indicate that SLITone^ULTRA®^ has a good safety profile. The duration of the treatment with this product seems to be the primary factor associated with the occurrence of AEs. However, studies with a larger number of patients have to be designed.
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###### 

Influence of different factors in the occurrence of adverse reactions

                                                                  Patients without adverse reactions   Patients with adverse reactions   *P*-value
  --------------------------------------------------------------- ------------------------------------ --------------------------------- --------------
  Sex, n (%)                                                                                                                             
   Female                                                         72 (75.8%)                           23 (24.2%)                        0.6417
   Male                                                           63 (78.8%)                           17 (21.3%)                        
  Age groups, n (%)                                                                                                                      
   5--9 years                                                     30 (75.0%)                           10 (25.0%)                        0.1801
   10--29 years                                                   66 (73.3%)                           24 (26.7%)                        
   30--76 years                                                   39 (86.7%)                           6 (13.3%)                         
  Time since the disease was diagnosed (years), median (Q1, Q3)   4.0 (3.0, 9.0)                       5.0 (3.0, 10.0)                   0.3800
  Asthma, n (%)                                                                                                                          
   Yes                                                            67 (72.0%)                           26 (28.0%)                        ***0.0847***
   No                                                             68 (82.9%)                           14 (17.1%)                        
  Clinical diagnosis, n (%)                                                                                                              
   Rhinitis, conjunctivitis, and asthma                           38 (70.4%)                           16 (29.6%)                        0.3354
   Rhinitis and asthma                                            29 (74.4%)                           10 (25.6%)                        
   Rhinitis and conjunctivitis                                    34 (81.0%)                           8 (19.0%)                         
   Rhinitis                                                       34 (85.0%)                           6 (15.0%)                         
  Composition of immunotherapy, n (%)                                                                                                    
   Grass                                                          21 (70.0%)                           9 (30.0%)                         0.6946
   *O. europaea*                                                  26 (81.3%)                           6 (18.8%)                         
   Grass + *O. europaea*                                          29 (74.4%)                           10 (25.6%)                        
   Dermatophagoides mix                                           23 (71.9%)                           9 (28.1%)                         
   *D. pteronyssinus*                                             28 (82.4%)                           6 (17.6%)                         
  Duration of treatment with SLITone^ULTRA®^, n (%)                                                                                      
   3 months                                                       78 (72.2%)                           30 (27.8%)                        ***0.0442***
   \>3 months                                                     57 (85.1%)                           10 (14.9%)                        
  Sensitization, n (%)                                                                                                                   
   Monosensitized                                                 70 (81.4%)                           16 (18.6%)                        0.1730
   Polysensitized                                                 64 (72.7%)                           24 (27.3%)                        
  Concomitant medication, n (%)                                                                                                          
   Yes                                                            89 (75.4%)                           29 (24.6%)                        0.5411
   No                                                             43 (79.6%)                           11 (20.4%)                        

**Note:** The values in bold italic mean values are statistically significant or close to statistical significance.

**Abbreviations:** *O. europaea*, *Olea europaea*; *D. pteronyssinus*, *Dermatophagoides pteronyssinus*.
